The outcome of acute respiratory distress syndrome (ARDS) may vary from complete recovery to multiorgan failure and death. The current study evaluates the prognostic performance of plasma uPAR and Neutrophil expression of CD64 in patients with ARDS of different etiologies and tests the possible correlation with other prognostic markers, namely APACHE-II score and serum CRP. The current study included 2 groups: 68 patients with ARDS and 25 age- and sex-matched, randomly selected, healthy control subjects. Blood samples were taken for routine laboratory tests on admission to ICU. Plasma uPAR was measured using a commercially available ELISA kit, and neutrophil CD64 expression was measured using flow cytometry. Plasma uPar was significantly higher in bacteremic ARDS patients than those without bacteremia. There was also a significant increase in plasma uPAR in ARDS survivors than in those who died. CD64 expression showed a similar pattern of increase in bacteremic ARDS. Using ROC curves plasma uPAR outperformed CD64 expression and CRP as a prognostic indicator in the studied ARDS patients. A cut-off value for plasma uPAR which almost always predicted mortality was 15.1 ng/ml with PPV of 100% and NPV 97%. Plasma uPAR is significantly elevated in ARDS patients and has a superior prognostic value to both neutrophil CD64 expression and scrum CRP in ARDS patients. A plasma uPAR cutoff value of 15.1 ng/ml has a PPV of 100% and NPV of 97% in predicting mortality in the ARDS patient included in the current study.
BhadadeRR, de SouzaRA, HardeMJ, KhotA. Clinical characteristics and outcomes of patients with acute lung injury and ARDS. J Postgrad Med2011; 57:286–90.
2.
StapletonRD, WangBM, HudsonLD, RubenfeldGD, CaldwellES, SteinbergKP. Causes and timing of death in patients with ARDS. Chest2005; 128:525–32.
3.
BerstenAD, EdibamC, HuntT, MoranJ; Australian and New Zealand Intensive Care Society Clinical Trials Group. Incidence and mortality of acute lung injury and the acute respiratory distress syndrome in three Australian States. Am J Respir Crit Care Med2002; 165:443–8.
4.
Navarrete-NavarroP, Ruiz-BailénM, Rivera-FernándezR, Guerrero-LópezF, Pola-Gallego-de-GuzmánMD, Vázquez-MataG. Acute respiratory distress syndrome in trauma patients: ICU mortality and prediction factors. Intensive Care Med2000; 26:1624–9.
5.
EscarceJJ, KelleyMA. Admission source to the medical intensive care unit predicts hospital death independent of APACHE II score. JAMA1990; 264:2389–94.
6.
CapuzzoM, ValpondiV, SgarbiA, Validation of severity scoring systems SAPS II and APACHE II in a single-center population. Intensive Care Med2000; 26:1779–85.
7.
RowanKM, KerrJH, MajorE, McPhersonK, ShortA, VesseyMP. Intensive Care Society's Acute Physiology and Chronic Health Evaluation (APACHE II) study in Britain and Ireland: a prospective, multicenter, cohort study comparing two methods for predicting outcome for adult intensive care patients. Crit Care Med1994; 22:1392–401.
8.
BajwaEK, KhanUA, JanuzziJL, GongMN, ThompsonBT, ChristianiD. Plasma C-reactive protein levels are associated with improved outcome in ARDS. Chest2009; 136:471–80.
9.
Groselj-GrencM, IhanA, DergancM. Neutrophil and monocyte CD64 and CD 163 expression in critically ill neonates and children with sepsis: comparison of fluorescence intensities and calculated indexes. Mediators Inflamm2008; 2008:202646.
10.
ChapmanHA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol1997; 9:714–24.
11.
Alpízar-AlpízarW, NielsenBS, SierraR, Urokinase plasminogen activator receptor is expressed in invasive cells in gastric carcinomas from high- and low-risk countries. Int J Cancer2010; 126:405–15.
12.
NykjaerA, MøllerB, ToddRF3rd, ChristensenT, AndreasenPA, GliemannJ, PetersenCM. Urokinase receptor: an activation antigen in human T lymphocytes. J Immunol1994; 152:505–16.
13.
De BockCE, WangY. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev2004; 24:13–39.
14.
OssowskiL, Aguirre-GhisoJA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migrationandgrowth. Curr Opin Cell Biol2000; 12:613–20.
15.
WittenhagenP, KronborgG, WeisN, NielsenH, ObelN, PedersenSS, Eugen-OlsenJ. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteracmia and predicts mortality. Clin Microbiol Infect2004; 10:409–15.
16.
BernardGR, ArtigasA, BrighamKL, The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med1994; 149:818–24.
17.
LevyMM, FinkMP, MarshallJC, 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med2003; 31:1250–56.
18.
KnausWA, DraperEA, WagnerDP, ZimmermanJE. APACHE II: a severity of disease classification system. Crit Care Med1985; 13:818–29.
19.
IcardiM, EricksonY, KilbornS, StewartB, GriefB, ScharnweberG. CD64 index provides simple and predictive testing for detection and monitoring of sepsis and bacterial infection in hospital patients. J Clin Microbiol2009; 47:3914–19.
20.
ShresthaGS, GurungR, AmatyaR. Comparison of Acute Physiology, Age, Chronic Health Evaluation III score with initial Sequential Organ Failure Assessment score to predict ICU mortality. Nepal Med Coll J2011; 13:50–54.
21.
TangW, ZhangXM, XiaoB, ZengNL, PanHS, FengZS, XuXX. Magnetic resonance imaging versus Acute Physiology And Chronic Healthy Evaluation II score in predicting the severity of acute pancreatitis. Eur J Radiol2011; 80:637–42.
22.
TaruiT, AkakuraN, MajumdarM, Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation. Thromb Haemost2006; 95:524–34.
23.
ShettyS, IdellS. Urokinase induces expression of its own receptor in Beas2B lung epithelial cells. J Biol Chem2001; 276:24549–56.
24.
PedersenH, BrunnerN, FrancisD, OsterlindK, RonneE, HansenHH, DanoK, Grondahl-HansenJ. Prognostic impact of urokinase, urokinase receptor, and type I plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res1994; 54:4671–75.
25.
PedersenH, Grondahl-HansenJ, FrancisD, OsterlindK, HansenHH, DanoK, BrunnerN. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res1994; 54:120–3.
26.
Gámez-DiazLY, EnriquezLE, MatuteJD, Diagnostic accuracy of HMGB-1, sTREM-1, and CD64 as markers of sepsis in patients recently admitted to the emergency department. Acad Emerg Med2011; 18:807–15.
27.
SedláckováL, PrûchaM, DostálM. [Immunological monitoring of sepsis using flow cytometry–quantitation of monocyte HLA-DR expression and granulocyte CD64 expression]. Epidemiol Mikrobiol Imunol2005; 54:54–61.
28.
De HaasM, VossebeldPJM, Von dem BorneAEGK, RoosD. 1995 Fc-receptors of phagocytes. J Lab Clin Med126:330–41.
29.
Sanchez-MejoradaG, RosalesC. Signal transduction by immunoglobulin Fc receptors. J Leukoc Biol1998; 63:521–33.
30.
SongSH. KimHK, ParkMM, ChoH-I. Neutrophil CD64 expression is associated with severity and prognosis of disseminated intravascular coagulation. Thromb Res2008; 121:499–507.
31.
DanikasDD, KarakantzaM, TheodorouGL, SakellaropoulosGC, GogosCAPrognostic value of phagocytic activity of neutrophils and monocytes in sepsis. Correlation to CD64 and CD 14 antigen expression. Clin Exp Immunol2008; 154:87–97.
32.
MüllerB, PeriG, DoniA, High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol2002; 72:643–9.
